Ginkgo Bioworks Holdings, Inc. is a biotech company. The company is headquartered in Boston, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2021-04-19. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The firm provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
Follow-Up Questions
Ginkgo Bioworks Holdings Inc 的 CEO 是誰？
Dr. Jason Kelly 是 Ginkgo Bioworks Holdings Inc 的 Chief Executive Officer，自 2021 加入公司。
DNA 股票的價格表現如何？
DNA 的當前價格為 $11.41，在上個交易日 decreased 了 1.52%。
Ginkgo Bioworks Holdings Inc 的主要業務主題或行業是什麼？
Ginkgo Bioworks Holdings Inc 屬於 Life Sciences Tools & Services 行業，該板塊是 Health Care
